Michael Thase of the Perelman School of Medicine discussed esketamine, a newly FDA-approved nasal spray developed to combat treatment-resistant depression. Derived from ketamine, the drug is meant to be administered under a doctor’s supervision due to the possibility of temporary anesthetic or hallucinogenic effects.

March 6, 2019 ・ From Philadelphia Inquirer